Centers for Disease Control and Prevention: National Diabetes Statistics Report, 2014. http://www.cdc.gov/diabetes/pubs/statsreport14/nationaldiabetes-report-web.pdf (accessed 10/12/2014).
Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005; 294: 1255-9.
Gregg EW, Gu Q, Cheng YJ, Narayan KM, Cowie CC. Mortality trends in men and women with diabetes, 1971 to 2000. Ann Intern Med 2007; 147: 149-55.
Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2005. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2005. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2005.pdf (accessed 9/9/2014).
Eckel RH, Kahn R, Robertson RM, Rizza RA. Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Circulation 2006; 113: 2943-6.
Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999; 100: 1134-6.
Mangano DT. Perioperative medicine: NHLBI working group deliberations and recommendations. J CardiothoracVascAnesth 2004; 18: 1-6.
Reynolds C. Management of the diabetic surgical patient. A systematic but flexible plan is the key. Postgrad Med 1985; 77: 265-9, 272-6, 279.
Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med 1996; 335: 1713-20.
Eagle KA, Brundage BH, Chaitman BR, Ewy GA, Fleisher LA, Hertzer NR, et al. Guidelines for perioperative cardiovascular evaluation for noncardiac surgery.Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.Committee on Perioperative Cardiovascular Evaluation for Noncardiac Surgery.Circulation 1996; 93: 1278-317.
Devereaux PJ, Goldman L, Cook DJ, Gilbert K, Leslie K, Guyatt GH. Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk. CMAJ 2005; 173: 627-34.
Sun JZ, Maguire D. How to prevent perioperative myocardial injury: the conundrum continues. Am Heart J 2007; 154: 1021-8.
Flaherty JD, Davidson CJ. Diabetes and coronary revascularization. JAMA 2005; 293: 1501-8.
Wouters PF. New perspectives for an old cure: a glucose-insulin-potassium revival in cardiac surgery? CurrOpinAnaesthesiol 2004; 17: 31-3.
Landesberg G, Luria MH, Cotev S, Eidelman LA, Anner H, Mosseri M, et al. Importance of long-duration postoperative ST-segment depression in cardiac morbidity after vascular surgery. Lancet 1993; 341: 715-9.
Landesberg G, Mosseri M, Zahger D, Wolf Y, Perouansky M, Anner H, et al. Myocardial infarction after vascular surgery: the role of prolonged stress-induced, ST depression-type ischemia. J Am CollCardiol 2001; 37: 1839-45.
Badner NH, Knill RL, Brown JE, Novick TV, Gelb AW. Myocardial infarction after noncardiac surgery.Anesthesiology 1998; 88: 572-8.
Lindenauer PK, Pekow P, Wang K, Mamidi DK, Gutierrez B, Benjamin EM. Perioperative beta-blocker therapy and mortality after major noncardiac surgery.N Engl J Med 2005; 353: 349-61.
Poldermans D, Boersma E, Bax JJ, Thomson IR, van de Ven LL, Blankensteijn JD, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery.Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med 1999; 341: 1789-94.
Buffington CW, Perez WJ. Perioperative myocardial ischemia and infarction. Atherosclerotic plaque rupture in coronary artery disease. Int Anesthesiol Clin 1992; 30: 217-35.
Dawood MM, Gutpa DK, Southern J, Walia A, Atkinson JB, Eagle KA. Pathology of fatal perioperative myocardial infarction: implications regarding pathophysiology and prevention. Int J Cardiol 1996; 57: 37-44.
Cohen MC, Aretz TH. Histological analysis of coronary artery lesions in fatal postoperative myocardial infarction. Cardiovasc Pathol 1999; 8: 133-9.
Hu A, Jiao X, Gao E, Koch WJ, Sharifi-Azad S, Grunwald Z, et al. Chronic beta-adrenergic receptor stimulation induces cardiac apoptosis and aggravates myocardial ischemia/reperfusion injury by provoking inducible nitric-oxide synthase-mediated nitrative stress. J Pharmacol Exp Ther 2006; 318: 469-75.
Hu A, Jiao X, Gao E, Li Y, Sharifi-Azad S, Grunwald Z, et al. Tonic beta-adrenergic drive provokes proinflammatory and proapoptotic changes in aging mouse heart. Rejuvenation Res 2008; 11: 215-26.
Taggart DP. Lessons learned from the SYNTAX trial for multivessel and left main stem coronary artery disease. Curr Opin Cardiol 2011; 26: 502-7.
Meliga E, Valgimigli M, Buszman P, Serruys PW. Percutaneous coronary intervention or coronary artery bypass graft for unprotected left main coronary artery disease: the endless debate. J Am Coll Cardiol 2008; 52: 582-4.
Hlatky MA, Bravata DM. Stents or surgery? New data on the comparative outcomes of percutaneous coronary intervention and coronary artery bypass graft surgery. Circulation 2008; 118: 325-7.
Daemen J, Boersma E, Flather M, Booth J, Stables R, Rodriguez A, et al. Long-term safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: a meta-analysis with 5-year patient-level data from the ARTS, ERACI-II, MASS-II, and SoS trials. Circulation 2008; 118: 1146-54.
Bravata DM, Gienger AL, McDonald KM, Sundaram V, Perez MV, Varghese R, et al. Systematic review: the comparative effectiveness of percutaneous coronary interventions and coronary artery bypass graft surgery. Ann Intern Med 2007; 147: 703-16.
Berry C, Tardif JC, Bourassa MG. Coronary heart disease in patients with diabetes: part II: recent advances in coronary revascularization. J Am Coll Cardiol 2007; 49: 643-56.
Hannan EL, Wu C, Walford G, Culliford AT, Gold JP, Smith CR, et al. Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. N Engl J Med 2008; 358: 331-41.
Javaid A, Steinberg DH, Buch AN, Corso PJ, Boyce SW, Pinto Slottow TL, et al. Outcomes of coronary artery bypass grafting versus percutaneous coronary intervention with drug-eluting stents for patients with multivessel coronary artery disease. Circulation 2007; 116: I200-6.
Mohr F, Serruys P. The SYNergy between percutaneous coronary intervention and cardiac surgery (SYNTAX) study. ESC 2008, Session number: 1690-1693.
Booth J, Clayton T, Pepper J, Nugara F, Flather M, Sigwart U, et al. Randomized, controlled trial of coronary artery bypass surgery versus percutaneous coronary intervention in patients with multivessel coronary artery disease: six-year follow-up from the Stent or Surgery Trial (SoS). Circulation 2008; 118: 381-8.
Mohr FW, Morice MC, Kappetein AP, Feldman TE, Ståhle E, Colombo A, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013; 381: 629-38.
Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35: 2541-619.
Capodanno D, Tamburino C. Unraveling the EXCEL: promises and challenges of the next trial of left main percutaneous coronary intervention. Int J Cardiol 2012; 156: 1-3.
BARI Investigators. The final 10-year follow-up results from the BARI randominzed trial. J Am CollCardiol 2007; 49: 1600-6.
Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, et al, FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012; 367: 2375-84.
Eagle KA, Rihal CS, Mickel MC, Holmes DR, Foster ED, Gersh BJ. Cardiac risk of noncardiac surgery: influence of coronary disease and type of surgery in 3368 operations. CASS Investigators and University of Michigan Heart Care Program.Coronary Artery Surgery Study.Circulation 1997; 96: 1882-7.
McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski WC, Littooy F, et al. Coronary-artery revascularization before elective major vascular surgery. N Engl J Med 2004; 351: 2795-804.
Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124: e652-735.
Leibowitz D, Cohen M, Planer D, Mosseri M, Rott D, Lotan C, et al. Comparison of cardiovascular risk of noncardiac surgery following coronary angioplasty with versus without stenting. Am J Cardiol 2006; 97: 1188-91.
Nuttall GA, Brown MJ, Stombaugh JW, Michon PB, Hathaway MF, Lindeen KC, et al. Time and cardiac risk of surgery after bare-metal stent percutaneous coronary intervention. Anesthesiology 2008; 109: 588-95.
Rade JJ, Hogue CW Jr. Noncardiac surgery for patients with coronary artery stents: timing is everything. Anesthesiology 2008; 109: 573-5.
Ward HB, Kelly RF, Thottapurathu L, Moritz TE, Larsen GC, Pierpont G, et al. Coronary artery bypass grafting is superior to percutaneous coronary intervention in prevention of perioperative myocardial infarctions during subsequent vascular surgery. Ann ThoracSurg 2006; 82: 795-800.
Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345: 1359-67.
Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354: 449-61.
NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair D, Foster D, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360: 1283-97.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.Lancet 1998; 352: 837-53.
Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-17.
Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, et al. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 2009; 119: 351-7.
Mitka M. Contradictory findings ignite questions about blood glucose targets in diabetes. JAMA 2008; 299: 1413-5.
Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59.
ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-72.
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-89.
Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-39.
Gandhi GY, Nuttall GA, Abel MD, Mullany CJ, Schaff HV, O'Brien PC, et al. Intensive intraoperative insulin therapy versus conventional glucose management during cardiac surgery: a randomized trial. Ann Intern Med 2007; 146: 233-43.
Lazar HL, Chipkin SR, Fitzgerald CA, Bao Y, Cabral H, Apstein CS. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation 2004; 109: 1497-502.
Furnary AP, Gao G, Grunkemeier GL, Wu Y, Zerr KJ, Bookin SO, et al. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J ThoracCardiovascSurg 2003; 125: 1007-21.
Kagansky N, Levy S, Rimon E, Cojocaru L, Fridman A, Ozer Z, et al. Hypoglycemia as a predictor of mortality in hospitalized elderly patients. Arch Intern Med 2003; 163: 1825-9.
Goldberg PA, Sakharova OV, Barrett PW, Falko LN, Roussel MG, Bak L, et al. Improving glycemic control in the cardiothoracic intensive care unit: clinical experience in two hospital settings. J Cardiothorac Vasc Anesth 2004; 18: 690-7.
McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycemia. Crit Care Clin 2001; 17: 107-24.
Goodarzi MO, Psaty BM. Glucose lowering to control macrovascular disease in type 2 diabetes: treating the wrong surrogate end point? JAMA 2008; 300: 2051-3.
Fleisher LA, Fleischmann KE, Auerbach AD, Barnason SA, Beckman JA, Bozkurt B, et al. 2014 ACC/AHA Guidelines on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 64: e77-137.
Juul AB, Wetterslev J, Gluud C, Kofoed-Enevoldsen A, Jensen G, Callesen T, et al. Effect of perioperative beta blockade in patients with diabetes undergoing major non-cardiac surgery: randomised placebo controlled, blinded multicentre trial. BMJ 2006; 332: 1482.
POISE Study Group, Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008; 371: 1839-47.
Liggett SB, Cresci S, Kelly RJ, Syed FM, Matkovich SJ, Hahn HS, et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med 2008; 14: 510-7.
Dandona P, Ghanim H, Brooks DP. Antioxidant activity of carvedilol in cardiovascular disease. J Hypertens 2007; 25: 731-41.
Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentrerandomised placebo-controlled trial. Lancet 2004; 364: 685-96.
Athyros VG, Papageorgiou AA, Symeonidis AN, Didangelos TP, Pehlivanidis AN, Bouloukos VI, et al.Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus. Angiology 2003; 54: 679-90.
Hindler K, Shaw AD, Samuels J, Fulton S, Collard CD, Riedel B. Improved postoperative outcomes associated with preoperative statin therapy. Anesthesiology 2006; 105: 1260-72.
Durazzo AE, Machado FS, Ikeoka DT, De Bernoche C, Monachini MC, Puech-Leao P, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J VascSurg 2004; 39: 967-75.
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355: 253-9.
Cao Z, Cooper ME. Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetes. Acta Diabetol 2012; 49: 243-54.
Shi P, Li Z, Young N, Ji F, Wang Y, Moore P , et al. The effects of preoperative renin-angiotensin system inhibitors on outcomes in patients undergoing cardiac surgery. J Cardiothorac Vasc Anesth 2013; 27: 703-9.
Barodka V, Silvestry S, Zhao N, Jiao X, Whellan DJ, Diehl J, et al. Preoperative rennin-angiotensin system inhibitors protect renal function in aging patients undergoing cardiac surgery. J Surg Res 2011; 167: e63-9.
Gerstein HC. Cardiovascular and metabolic benefits of ACE inhibition: moving beyond blood pressure reduction. Diabetes Care 2000; 23: 882-3.
Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. Drugs 2004; 64: 2537-65.
Patsopoulous NA. A pragmatic view on pragmatic trials. Dialogues Clin Neurosci 2011; 13: 217-24.
Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression.New insights into prevention of plaque disruption and clinical events in coronary disease.Circulation 1993; 87: 1781-91.
Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 2002; 8: 1257-62.
Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-91.